Table 2.
Patient Characteristics and Univariate Analysis.
| Factors | N | OS | PFS | ||
|---|---|---|---|---|---|
| 5-Year OS (%) | P | 5-Year PFS (%) | P | ||
| Age, year | |||||
| ≤60 | 78 | 46.2 | .102 | 36.8 | .140 |
| >60 | 67 | 33.2 | 25.9 | ||
| Sex | |||||
| Male | 111 | 32.8 | .165 | 27.9 | .240 |
| Female | 34 | 48.0 | 44.1 | ||
| Tumor length | |||||
| <3 cm | 37 | 53.5 | .002 | 61.5 | .002 |
| ≥3 cm | 108 | 30.0 | 23.9 | ||
| Differentiation | |||||
| Well | 17 | 40.3 | .006 | 38.6 | .032 |
| Moderately | 90 | 39.4 | 30.7 | ||
| Poorly | 38 | 24.0 | 24.7 | ||
| T stage | |||||
| T1 | 13 | 82.5 | .000 | 72.9 | .001 |
| T2 | 34 | 48.9 | 37.2 | ||
| T3 | 64 | 31.7 | 28.5 | ||
| T4 | 34 | 18.8 | 19.1 | ||
| N stage | |||||
| N0 | 55 | 47.4 | .000 | 52.1 | .000 |
| N1 | 55 | 33.5 | 32.5 | ||
| N2 | 30 | 5.3 | 5.8 | ||
| N3 | 5 | 0 | 0 | ||
| PTEN | |||||
| Low | 84 | 29.7 | .044 | 24.2 | .140 |
| High | 61 | 45.7 | 43.7 | ||
| PI3K | |||||
| Low | 124 | 34.4 | .932 | 31.5 | .800 |
| High | 21 | 45.5 | 35.1 | ||
| AKT | |||||
| Low | 82 | 38.2 | .250 | 31.5 | .168 |
| High | 63 | 33.3 | 30.6 | ||
| p-AKT | |||||
| Low | 77 | 39.1 | .064 | 34.5 | .072 |
| High | 68 | 32.8 | 27.8 | ||
| mTOR | |||||
| Low | 74 | 46.3 | .011 | 39.2 | .010 |
| High | 71 | 25.6 | 23.2 | ||
| p-mTOR | |||||
| Low | 67 | 47.6 | .053 | 49.2 | .015 |
| High | 78 | 28.9 | 21.3 | ||
| 4E-BP1 | |||||
| Low | 87 | 41.3 | .074 | 33.1 | .159 |
| High | 58 | 28.5 | 27.9 | ||
| p-4E-BP1 | |||||
| Low | 93 | 35.7 | .373 | 37.8 | .279 |
| High | 52 | 35.8 | 24.9 | ||
| P70S6K1 | |||||
| Low | 77 | 43.3 | .009 | 40.7 | .007 |
| High | 68 | 27.8 | 21.4 | ||
| p-P70S6K1 | |||||
| Low | 86 | 41.7 | .106 | 38.4 | .171 |
| High | 59 | 27.5 | 21.7 | ||
Abbreviations: 4E-BP1, elongation initiation factor 4E binding protein-1; mTOR, mammalian target of rapamycin; OS, overall survival; P70S6K1, P70S6 kinase 1; PFS, progression-free survival; PI3K, phosphoinositide-3 kinase; PTEN, phosphatase and tensin homolog. Bold values mean significant difference.